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Abstract
Purpose Disproportionality screening analysis is acknowl-
edged as a tool for performing signal detection in databases
of adverse drug reactions (ADRs), e.g., in the European Union
(EU) Drug Authority setting. The purpose of this study was to
explore the possibility of decreasing false-positive signals of
disproportionate reporting (SDR) by calculating the propor-
tional reporting ratio (PRR)-by-therapeutic area (TA), while
still maintaining the ability to detect relevant SDRs.
Methods In the EudraVigilance (EV) Database, output from
PRR calculated with a restricted TA comparator background
was compared in detail to output from conventional authority-
setting PRR calculations for four drugs: bicalutamide,
abiraterone, metformin, and vildagliptin, within the TAs of
prostate gland disease and type 2 diabetes mellitus.
Results ADR reports per investigated drug ranged from 2,400
to 50,000. The PRR-TA’s ability to detect true-positive SDRs
(as acknowledged in approved labeling) was increased com-
pared to the conventional PRR, and performed 8–31 % better
than a recently proposed stricter EU-SDR definition. The
PRR-TA removed false SDRs confounded by disease or dis-
ease spill-over by up to 63 %, while retaining/increasing the
number of unclassified SDRs relevant for manual validation,
and thereby improving the ratio between confounded SDRs
(i.e., noise) and unclassified SDRs for all investigated drugs
(possible signals).
Conclusions The performance of the PRR was improved by
background restriction with the PRR-TA method; the number
of false-positive SDRs decreased, and the ability to detect true-
positive SDRs increased, improving the signal-to-noise ratio.
Further development and validation of the method is needed
within other TAs and databases, and for disproportionality
analysis methods.
Keywords PRR . Adverse drug reactions . ADR . Signal
detection . Pharmacovigilance . Disproportionality analysis
Introduction
Screening for statistical disproportionality in databases of
adverse drug reactions (ADRs) is an acceptedmeans for signal
detection. To improve patient safety, signal detection is
performed by drug companies, national competent authori-
ties, and independent pharmacovigilance stakeholders. Sev-
eral disproportionality methods are currently in use [1–5],
but no gold standard has been established [6, 7]. They all
share the ability to detect drug safety signals years earlier
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than traditional manual methods [8, 9]. Strengths, limita-
tions, and differences between different pharmacovigilance
signal detection methods including disproportionality
methods have been analyzed and described previously
[10], and are not the subject of this article.
Within the European Union (EU), the EudraVigilance (EV)
database [11] is continuously screened using the propor-
tional reporting ratio (PRR) method [1, 3, 12]. This method
delivers signals of disproportionate reporting (SDRs)—
reported ADR-drug combinations that (1) appear to a
disproportionately high extent in a database (have an
elevated PRR value), and (2) reach a case count above
a pre-specified threshold.
An SDR is merely a statistical finding that does not
imply a causal relationship between a drug and the ADR
[13]. Large amounts of SDRs are regularly delivered for
manual validation within the EU system from continuously
ongoing EV-PRR screening procedures. The PRR method
is sensitive, but the majority of SDRs delivered represent
noise, from e.g., statistical chance findings, artifacts, al-
ready acknowledged ADRs, confounding by disease, or by
“disease spill-over”, i.e. aspects of the treated disease
coded as an ADR. While a minority of false SDRs is
easily dismissible as non-signals, most require expert
knowledge of the drug and the disease to be rejected.
Attempts to improve the method’s performance and there-
by conserve manual expert resources within the EU have
recently included altering the numerical threshold defining
an SDR by increasing the required case count from the
conventionally used 3–5 at present [14]. This, however,
incurs an inevitable delay in the delivery of new SDRs
and the detection of signals.
Improving the performance of disproportionality analysis
methods by increasing the signal-to-noise ratio would thus be
important. We attempted to reduce the background noise of
false positive SDRs confounded by disease and disease spill-
over within the EU signal detection system. The novel method
investigated, hereafter called PRR-by-therapeutic area (PRR-
TA), uses logically restricted comparator backgrounds for the
PRR calculations in drugs for common therapeutic areas.
Outputs were compared to conventional PRR calculations
using the full EV database background. Comparisons were
made using the conventional SDR-defining case count of 3,
previously used within the common EU, compared to the
recently suggested threshold of 5. Additionally, we compared
the PRR-TA method’s ability to detect true-positive SDRs
compared to the PRR. Further, the impact of the masking
phenomenon [17], usually particularly evident in commercial
databases [18], was explored.
Pilots analyzed were four different drugs for chronic dis-
ease: bicalutamide, abiraterone, metformin, and vildagliptin,
within the two therapeutic areas of prostate gland disease and
type 2 diabetes mellitus (T2DM).
Material and methods
Database
The ADR database used was the EV, used for signal detection
purposes by drug authorities within the EU, including the
European Medicines Agency. All serious ADRs reported
worldwide for all drugs approved within the EU are mandated
to be reported to the EV from all marketing authorization
holders and EU drug authorities. The database is available
online for drugs centrally approved within the EU [15]. The
ADRs are coded using the MedDRA terminology [16].
New EU-PhV legislation that came into effect in July
2012 included alterations in reporting rules and definitions
of ADRs. Therefore, ADR data until a cut-off date June 30,
2012, were included for analysis. All data used in the study
are strictly on a group level; no individual case reports or
identifiable patient data was used. Hence, according to
applicable legislation, no approval from the ethics review
board was needed for the study.
Proportional reporting ratios, thresholds
Signals of disproportionate reporting (SDRs) for the four
investigated pilot drugs were identified by calculating the
proportional reporting ratio (PRR) [3] for all suspect drug-
ADR combinations on a MedDRA preferred term (PT) level
in EV (Supplementary Table 1). The SDRs were delivered
from the PRR calculations using the a priori defined cut-off
thresholds: both (a) a case count of ≥3 (SDR3) in EV, and (b) a
lower 95 % confidence interval of the PRR of>1.0, as were
recommended within the EU at the time of the study initiation.
A higher case count threshold of ≥5 cases (SDR5) for identi-
fying an SDR, recently introduced in the EU/ EMA system,
was analyzed for comparison. In this first step throughput
screening, no stratification was performed, in line with EU
standard procedure.
The method investigated, hereafter called 'PRR-by-
therapeutic area (PRR-TA)' restricts the background for com-
parison (b, d in Supplementary Table 1) to consist of drugs
from the two respective therapeutic areas instead of all drugs
in the EV.
Therapeutic areas
The two therapeutic areas chosen were (a) prostate gland
disease, with hormonally active drugs used for prostate cancer
(PrC) and benign prostate hyperplasia (BPH), and (b) T2DM,
excluding insulin replacement therapy. The drugs selected
within the selected TAs were: bicalutamide, abiraterone,
metformin, and vildagliptin, representing different time win-
dows of a drug life cycle; from long-term, well-established
to newly marketed drugs.
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Prostate gland disease
The prostate gland disease drugs studied were the well-
established bicalutamide (approved in the 1990s) and the
more recently approved abiraterone (EU, 2011), both indicat-
ed for PrC.
The PRR-TA calculations for prostate gland disease used
as background all drugs from ATC-codes L02AE, L02BB,
L02BX, G04CA, and B, and were performed with a sequen-
tially more restricted background, seen in models 1-4:
1. PRR: bicalutamide or abiraterone vs. the whole EV
database
2. PRR-TA: bicalutamide or abiraterone vs. drugs indicated
for PrC or BPH
3. PRR-TA: bicalutamide or abiraterone vs. drugs indicated
for PrC only
4. Drug class PRR: bicalutamide vs. other anti-androgens
For abiraterone, being the only approved drug in its class,
no model 4 calculation was applicable. As some BPH drugs
have other indications than BPH and to decrease the effect
of any off-label use, calculations in models 1–4 were
performed both with and without restricting them in order
to include reports specified as occurring in male patients
(supplementary data).
Type 2 diabetes mellitus
The T2DM example drugs studied were the well-established
metformin (approved in the 1950s) and the more recently
approved vildagliptin (EU 2008).
The PRR-TA calculations for T2DM used as background
all drugs from ATC-code A10B and were performed with a
sequentially more restricted background, seen in models 5-8
below. ADR reports on predefined, fixed-dose combination
products were not included.
5. PRR: metformin or vildagliptin vs. the whole EV database.
6. PRR-TA: metformin or vildagliptin vs. non-insulin anti-
diabetic drugs
7. Drug class PRR: metformin vs. biguanides
8. Drug class PRR: vildagliptin vs. DPP4-inhibitors
Acknowledged ADRs in the summary of product
characteristics
As a reference of acknowledged (true-positive) ADRs, the EU
Summaries of Product Characteristics (SPCs) as per July 2012
were used for vildagliptin and abiraterone, while SPCs for
originator and generic products were combined to determine
acknowledged ADRs for metformin and bicalutamide.
Validation
We conducted a comparative analysis of the ability to detect
acknowledged ADRs, i.e., positive controls of true-positive
SDRs, and to reduce noise from SDRs confounded by disease
and disease spill-over by using the PRR-TA SDR3 and the
SDR5.
SDRs delivered in models 1-8, shown above, were indepen-
dently evaluated and classified by experienced clinical experts
in the field of oncology, diabetology, and pharmacovigilance as
either
A. True-positive SDRs (i.e., acknowledged ADRs in the
SPCs for each drug) or
B. Other SDRs representing terms not acknowledged as
ADRs in the SPCs. These were in turn separated into:
C. False positive SDRs confounded by indication or by
indication spill-over (i.e., irrelevant for further evaluation),
and
D. Unclassifiable SDRs, relevant for further manual validation
as possible new signals.
Results from the classification were compared and the
differences obtained were resolved by consensus with refer-
ence to standard literature.
For bicalutamide, 950 different ADR terms had been
reported (Supplementary Table 2), PRR calculation delivered
95 of these as SDR3s, and these were thus classified into
groups of “A” or “B” and the “B” group was in turn separated
into “C” or “D”.
Possible masking/de-masking of SDRs by using restricted
backgrounds for the PRR calculations was evaluated by
comparing true-positive SDRs, the “A”s, in the respective
models. The concordance between the methods was hereby
evaluated.
A comparative analysis of the ability of models 1-8 to
deliver true-positive SDRs, “A”s, was performed, defining
this ability as the percentage of acknowledged ADR terms in
the SPC detected by the method. A similar analysis using the
SDR5 in models 1 and 5, respectively, was also performed.
The number of delivered SDRs from the “C” (false posi-
tives) and “D” (unclassifiable and therefore, relevant) groups
using models 1-8 was identified and compared. A similar
comparison using the SDR5 in models 1 and 5, respectively,
was also performed.
Statistics
Statistical calculations of the PRR-TA were made using the
open access tool “R” [19, 20], except for the analyses of the
full EV database (models 1 and 5) for standard PRR using the
EV Data WareHouse Tool.
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Formal calculations of the different PRRmethods’ accuracy,
i.e., the “usual” two-by-two table to calculate the sensitivity,
specificity, and positive predictive value, are not applicable.
Several SDRs often represent similar events and may point
to one broader reference ADR term acknowledged as a true
ADR in the respective SPCs, thus making detection of true
positives ambiguous. Further, true-negative SDRs cannot be
firmly established, as it is in this group that the new, not-yet-
established ADRs are to be detected. Instead, we used a proxy
measurement of the positive predictive properties of the
methods’, calculated as a ratio between the number of false
positive SDRs, “C”, and the unclassifiable, relevant SDRs,
“D”, for models 1-8.With presumed ideal noise reduction by a
decreased numerator “C” and preserved or increased denom-
inator, “D” the C/D -ratio should approach zero.
Results
The number of ADR reports for the four investigated drugs
ranged from 2,400 for abiraterone to close to 50,000 for met-
formin (Supplementary Table 2). To compare: the total number
of ADR reports for all drugs in the EV database was roughly
3.5 million. The average number of ADR reports per ADR
term was 18 for metformin and 5 for bicalutamide, abiraterone,
and vildagliptin, mirroring the on-the-market times.
Conventional PRR calculations using the SDR3 and SDR5
thresholds
Relative frequencies of SDRs using 3 as the case count
threshold (SDR3) among all reported ADR terms ranged from
10 % for bicalutamide (i.e. 95/950) to 17.9 % for vildagliptin
(Supplementary Table 2)' the rest, 82–90 %, were thereby
excluded from clinical evaluation. Increasing the SDR-
defining case count to ≥5 (SDR5) reduced the number of
SDRs for further validation and verification by between
14 % in the abiraterone (men only) analysis and 36 % for
vildagliptin, also removing between 33–70 % of unclassified
SDRs, potentially delaying detection and validation of impor-
tant signals (Supplementary Table 2).
PRR calculations by restricting the background
of comparison; detection of acknowledged ADRs
in SPCs, i.e. true-positive SDR
The PRR-TA’s ability to detect and deliver true-positive SDRs
compared to the conventional PRR method using SDR3 or
SDR5 thresholds are presented in Fig. 1a-d. For bicalutamide,
abiraterone, and vildagliptin, this ability was increased or
unchanged (Fig. 1a, b, d). For metformin, the PRR-TA failed
to deliver one of the twelve ADR terms delivered by the
conventional PRR method (Fig. 1c).
Using the more strict SDR5 threshold (far right bar in
Fig. 1a-d), led to a failure of the PRR to identify between 5–
20% of acknowledged ADRs as compared to using the SDR3
threshold. Applying the SDR5 threshold with the PRR failed
to identify between 8–31 % compared to the PRR-TA method
applying the SDR3.
Reducing the background further down to drug class re-
sulted in a marked loss of ability to detect true-positive SDRs
in the bicalutamide/anti-androgen (model 4) and vildagliptin/
DPP4I (model 8) analyses, and an absence of ability to detect
any true-positive SDRs in the metformin/biguanides analysis
(model 7), indicating that models 4, 7, and 8 were not useful.
Analyses restricted to male gender for bicalutamide and
abiraterone did not differ markedly compared to analyses
including both genders; however, they appeared to perform
less well (Supplementary Fig. 4–6).
The ability to detect true-positive SDRs by the PRRs
methods using SDR 3 and SDR5 thresholds and the inter-
method concordance using different backgrounds in models
1–8 were high for each drug investigated. A few true-positive
SDRs were de-masked using the PRR-TA compared to con-
ventional PRR. For all drugs, the ability to detect true-positive
SDRs using the PRR-SDR5 was generally lower than for the
PRR-SDR3 and the PRR-TAs.
PRR calculation by restricting the background of comparison.
Detection of SDRs not acknowledged as ADRs in the SPCs
Figure 2 a-b represents the PRR-TA method’s ability to detect
and deliver SDRs not acknowledged as ADRs in the SPCs for
each drug, either false-positive SDRs confounded by disease
or disease spill-over (grey bars), or unclassified SDRs relevant
for further manual validation (black bars).
The number of false-positive SDRs confounded by disease or
disease spill-over, and thus less relevant for further evaluation,
decreased when moving from the conventional PRR analysis to
the PRR-TA (grey bars, from left to right in respective figures)
for all drugs except for abiraterone analysis (men only; Fig. 2b).
The number of unclassified SDRs relevant for further man-
ual validation, increased (black bars) when moving from the
conventional PRR analysis to the PRR-TA (from left to right
for each drug) for all drugs except for metformin.
Reducing the background further down to drug class de-
livered for metformin and bicalutamide (models 4, 7) few or
no unclassified SDRs relevant for manual validation, while for
vildagliptin (model 8), the numbers were maintained. Drug-
class level PRR thus appeared less useful.
Analyses restricted to male gender for bicalutamide and
abiraterone did not differ markedly compared to non-restricted
analyses (Supplementary Fig. 4–5).
The ratio between false-positive SDRs confounded by
indication or disease spill-over vs. unclassified SDRs relevant
for further manual validation is visualized in Fig. 3. From left
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to right in the figure, the ratio for each of the drugs is consis-
tently improved when decreasing the comparator background
from the conventional PRR (SDR3) output to the PRR-TA.
Analyses restricting the background down to drug class
(models 4, 7, 8) were not considered relevant to include in this
analysis based on their poor performance regarding the ability
to detect true-positive SDRs and remove false-positive SDRs.
Discussion
Main findings
Our study evaluates a novel approach of using the PRRmethod
as the first step in a high throughput of disproportionality
screening analysis—the PRR by therapeutic area (PRR-TA)
using a background restriction, specifically in a drug authority
pharmacovigilance standard setting. The evaluation of the
PRR-TA is exemplified by drugs from areas of chronic disease:
prostate gland disease and type 2 diabetes mellitus.
The PRR-TA performed better or equally well regarding its
ability to detect true-positive SDRs and to reduce the noise in
the form of false-positive SDRs, compared to the conventional
PRR. A significant proportion of acknowledged ADRs were,
however, not detected in any of the models often representing
very general ADRs acknowledged for occurring with many
drugs in the database, such as headache or nausea. The PRR-
TA decreased the ratio between false-positive SDRs vs. un-
classified SDRs relevant for further evaluation, i.e., improving
the signal-to-noise relationship compared to the conventional
Fig. 1 a-d The proportion of
detected acknowledged ADRs,
i.e., true-positive SDRs for
bicalutamide (a), abiraterone (b),
metformin (c), and vildagliptin
(d) using from left to right for
(a, b): the conventional PRR
defining the SDR by a case count
of ≥3 (model 1, SDR3); PRR-TA,
prostate gland disease drugs
(model 2, SDR3) ; PRR-TA
prostate cancer drugs (model 3,
SDR3); PRR-class (model 4,
SDR3, not for abiraterone); and
the conventional PRR defining
the SDR by a case count of ≥5
(model 1, SDR5). (c, d) From left
to right, the conventional PRR
defining the SDR by a case count
of ≥3 (SDR3); the PRR-
TA(SDR3); PRR-class(SDR3);
and the conventional PRR
defining the SDR by a case count
of ≥5 (SDR5)
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PRR. Results from the most restricted backgrounds, the drug
classes, were not satisfying for signal detection purposes, as
their ability to detect true-positive SDRs was poor; this also
confirmed the inherent feature of all signal detection methods
in that the lack of detection of an SDR does not imply a lack of
a causal relationship between a drug and a reported ADR.
The encouraging results when including drugs for the
treatment of both BPH and PrC into one therapeutic area
suggest that the indication for treatment of included drugs
does not have to be identical in a restricted background
database for the method to apply. It appears to suffice that
the symptoms of the treated disease areas are largely
coinciding.
The PRR-TA furthermore performed better for background
noise reduction than the recently implemented method in the
EU of restricting the number of SDRs delivered by increasing
the threshold case count to ≥5 instead of ≥3. Analyses restricted
by gender for the prostate gland disease analyses did not
markedly improve the outcome, implying that gender restric-
tions may be less useful than restriction to therapeutic area,
even in gender-specific drugs/therapeutic areas.
Comparison with literature
A recent general guidance review on practical aspects on
pharmacovigilance methodology briefly discusses a possible
impact on disproportionate analyses from restricting the back-
ground or by stratification [10]. However, this is predominate-
ly suggested for the area of vaccines and pediatric drugs due to
their particular use and target population. Among seven pos-
sible sources of improvements in signal detection suggested
by others [21] is: “selection of appropriate control groups and
Fig. 2 a-b The PRR, PRR-TAs,
and the PRR class methods’
ability to detect and deliver SDRs
not acknowledged as ADRs in the
SPCs for each drug, either false-
positive SDRs confounded by
disease or disease spill-over
(grey bars) or unclassified SDRs
relevant for further manual
validation (black bars); Fig 2a:
bicalutamide and abiraterone,
Fig 2b: metformin and
vildagliptin analyses
Fig. 3 The ratio of false-positive SDRs confounded by indication or
disease spill-over and unclassified SDRs relevant for further manual
validation; the ratio should ideally be as close to zero as possible, with
as few confounded SDRs as possible (numerator) delivered by the
method in relation to the relevant SDRs (denominator). From left to right
for each drug analysis: the ratios when analyzing by the conventional
PRR, PRR-TA (model 2 and 6), and for bicalutamide and abiraterone,
also the PRR-TA (model 3)
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restriction to subsets of people/reports”. It has been suggested
that subgroups of a database could be used as a background
for disproportionate analyses [22], by e.g., removing per-orals
when analyzing injectables, chemotherapeutics when evaluat-
ing emesis for other drugs or, all ADR terms in the back-
ground that do not appear for a drug under investigation [22].
This has been exemplified with single-drug-ADR pairs, but no
general analysis has been presented.
Few studies on the systematic analysis of results from
background alterations for disproportionality methods have
been published—these almost exclusively concerning the area
of analyzing (pediatric-) vaccines [23–25]. Increased numbers
of false negatives have been noted in such analyses [25], and
only subsamples of SDRs (5–10 %) were analyzed in clinical
detail. Stratification for age, gender, and/or alteration of back-
ground databases resulted in differences in the output from
disproportionality analyses [23, 24] in vaccines, with low
concordance in some cases [23] recommending combined
analyses [24], and highlighting that “stratification likely in-
creased efficiency” [23].
Published studies generally represent a statistics perspec-
tive on explorations of variants of restricted (vaccine) back-
grounds or stratification in disproportionality analyses, again
with only minor samples of the output analyzed in clinical
detail [25]. The present study instead focuses on the clinical
patient perspective, i.e., on the therapeutic area classifying
each SDR in detail to determine its relevance. Furthermore,
practical and generalizable conclusions drawn from vaccine
signal detection studies are not applicable for long-term-use
drugs, with vaccines being used on few occasions in a healthy,
young population. Our study populations are in this respect
more representative of long-term drug users in general, re-
garding variations in age, background morbidity, and drug
administration forms.
The masking phenomenon from isolated drugs or ADRs
may have a large impact on analyses, especially in commercial
databases in which single drugs may constitute a large pro-
portion of the reports [18, 24, 26–28]. We noted only sporadic
cases of de-masking of acknowledged ADRs/SDRs in the
PRR-TA compared to the PRR. The further evaluation of the
phenomenon of de-masking by removing established ADR-
drug associations from the background, as others have both
hypothesized and performed [29, 30], could be another way of
improving the screening performance.
Methods to measure and compare the general performance
of disproportionality methods in ADR databases are under
development, e.g., from OMOP collaboration [31], by using
standard collections of positive and negative controls for drug-
event-combinations (DECs). Such methods are not applicable
for measuring the results of detailed analyses of individual
drugs such as in our PRR-TA pilot study, as they are com-
prised only of a few selected controls per drug across a full
database, rather than covering all ADRs acknowledged for a
specific drug. The OMOP data were therefore not relevant for
measurement in our study.
Strengths and weaknesses of the PRR-TA
The PRR-TA reduced the background noise to a higher extent
than was reached through restricting the number of signals by
redefining, i.e., increasing the SDR threshold of the PRR from
SDR3 to SDR5.
A strength of the PRR-TA is the possibility to avoid the
inevitable delayed signal detection incurred by an increased
case count threshold from 3–5, i.e., the delay while awaiting
cases #4 and #5. This is especially relevant for orphan drugs or
other drugs that are used less frequently.
An inherent weakness of the PRR-TA, shared with all
disproportionate methods, is the poor ability to detect ADRs
mimicking symptoms of the treated disease or opposite para-
doxical reactions [32]. Such SDRs will likely be discarded
early at the following step, i.e., the manual expert validation.
Validation of a signal following a disproportionality analysis
normally includes ascertaining reliable information on the
background incidence of the suspected new ADR in the
population at risk, i.e., in patients with the same disease
without treatment with the drug in question. The PRR-TA
partly incorporates this.
The PRR-TA thus represents a way of introducing
established clinical knowledge early in the primary statistical
disproportionality analysis, providing the manual evaluators
the possibility to focus on relevant SDRs, with reduced noise
from irrelevant SDRs.
Clinical and scientific implications
This study explored new methods for signal detection,
intending to decrease background noise while maintaining
the ability to detect true signals. The PRR-TA method pro-
vides an opportunity to standardize data in order to improve
the output in a large, general database.
Importantly, the therapeutic use in our study is the factor for
clustering drugs rather than the ATC code, as the latter would
presumably not be as sufficient for the reduction of SDRs
representing confounding of disease and disease spill-over.
The PRR-TAwould, if proven generalizable to other ther-
apeutic areas, provide opportunity for a more cost-efficient
use of manual expert resources in the ensuing signal validation
step. Others have previously emphasized “the importance of
minimizing the amount of false-positive signals (SDRs) that,
if excessive, could detract from optimal pharmacovigilance
activities” [24].
Advanced stratification or using advanced, complex statis-
tical methods may provide an exaggerated confidence, i.e.,
“seduction bias” [33] as to what disproportionality methods
may do. More complex analysis methods do not necessarily
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yield better output, especially if used at the expense of clinical
expertise. Even if a signal-to-noise ratio or other features of a
disproportionality analysis method are improved, these
methods can indeed still be used only for screening purposes.
The ensuing manual clinical expert evaluation is indispens-
able in determining whether a delivered SDR should be con-
sidered a signal or not.
The PRR-TAmethod balances well themethod's complexity
in relation to clinical knowledge in the areas exemplified.
Unanswered questions and future research specified
The PRR-TA was performed in our study for drugs with a
single approved indication in a very large general ADR data-
base. Other drugs and their respective therapeutic areas would
have to be analyzed before a wider use could be recommended.
For drugs with more than one approved indication within
diverse TAs, TA definitions also need further exploration. The
method may be useful in other database settings or with other
disproportionality methods, but this would similarly have to be
validated before applying it in signal detection routine. If proven
generalizable, the PRR-TAwould have the potential to improve
the output of screening methods currently used in the EU. At
this point, our results would suffice to merit the use of the PRR-
TA method in conjunction with conventional methods.
Conclusions
The PRR-TA method, i.e., adapting the PRR method by
therapeutic areas, suggests a potential to decrease the number
of false-positive SDRs confounded by indication and indica-
tion spill-over. Further, the PRR-TA maintains the ability to
detect true-positive SDRs in drugs for chronic diseases using
the SDR threshold of three, i.e., without introducing inevitable
delays of waiting for the fourth and fifth reports. We empha-
size that exploring and validating the method’s applicability
also in other treatment areas is needed to establish its position
among present tools for signal detection, considering their
different advantages and disadvantages. A conventional PRR
methodmay not be replaced at present, rather the PRR-TAmay
be used in conjunction. If found to be generalizable into other
therapeutic areas, this tool could increase the effectiveness of
valuable manual validation resources.
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